Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Inflammatory Bowel Diseases

Free Subscription 09.09.2024 1 Aliment Pharmacol Ther 1 Am J Gastroenterol 2 Dig Dis Sci 1 Eur J Gastroenterol Hepatol 2 Gastroenterology 7 Inflamm Bowel Dis 4 J Crohns Colitis 2 Lancet Gastroenterol Hepatol 1 Minerva Gastroenterol (Torino) 1 PLoS One 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Aliment Pharmacol Ther

1. GRELLIER N, Kirchgesner J, Uzzan M, McLellan P, et al
   Early ileal resection in Crohn's disease is not associated with severe long-term outcomes: The ERIC study.
   Aliment Pharmacol Ther. 2024 Sep 5. doi: 10.1111/apt.18247.
   PubMed         Abstract available
   
   

   
   Am J Gastroenterol

2. VAUGHN BP, Khoruts A, Fischer M
   Diagnosis and management of Clostridioides difficile in inflammatory bowel disease.
   Am J Gastroenterol. 2024 Sep 4. doi: 10.14309/ajg.0000000000003076.
   PubMed         Abstract available
   
   

   
   Dig Dis Sci

3. GRAY C, Shakir R, Tumin D, Mandelia C, et al
   Predictors of Unplanned Health Care Utilization Among Children with Inflammatory Bowel Disease in a Rural Region of the Southeastern US.
   Dig Dis Sci. 2024 Sep 3. doi: 10.1007/s10620-024-08619.
   PubMed         Abstract available
   
   
4. CHEN KA, Gartner V, Darlington KC, Silverstein SR, et al
   Post-operative Crohn's Disease Recurrence and Infectious Complications: A Transcriptomic Analysis.
   Dig Dis Sci. 2024 Aug 31. doi: 10.1007/s10620-024-08595.
   PubMed         Abstract available
   
   

   
   Eur J Gastroenterol Hepatol

5. DAUNGSUPAWONG H, Wiwanitkit V
   Evaluation of online chat-based artificial intelligence responses about inflammatory bowel disease and diet: correspondence.
   Eur J Gastroenterol Hepatol. 2024;36:1243.
   PubMed        
   
   

   
   Gastroenterology

6. OLIVERA PA, Martinez-Lozano H, Leibovitzh H, Xue M, et al
   Healthy first-degree relatives from multiplex families versus simplex families have a higher subclinical intestinal inflammation, a distinct fecal microbial signature, and harbor a higher risk of developing Crohn's disease.
   Gastroenterology. 2024 Sep 3:S0016-5085(24)05414.
   PubMed         Abstract available
   
   
7. LU C, Feagan BG, Fletcher JG, Baker M, et al
   Management of Small Bowel Crohn's Disease Strictures: To cut, to stretch or to treat inflammation?
   Gastroenterology. 2024 Aug 31:S0016-5085(24)05413.
   PubMed        
   
   

   
   Inflamm Bowel Dis

8. GUO X, Zhao Z, Wang Y
   Refining the Understanding of Cannabis Impact on Inflammatory Bowel Disease Outcomes: Recommendations for Enhanced Research and Healthcare Practices.
   Inflamm Bowel Dis. 2024 Sep 6:izae207. doi: 10.1093.
   PubMed        
   
   
9. PANES J, Louis E, Bossuyt P, Joshi N, et al
   Induction of Endoscopic Response, Remission, and Ulcer-Free Endoscopy With Upadacitinib Is Associated With Improved Clinical Outcomes and Quality of Life in Patients With Crohn's Disease.
   Inflamm Bowel Dis. 2024 Sep 4:izae200. doi: 10.1093.
   PubMed         Abstract available
   
   
10. BERNSTEIN CN, Fisk JD, Walld R, Bolton JM, et al
    Psychiatric Comorbidity Does Not Enhance Prescription Opioid Use in Inflammatory Bowel Disease as It Does in the General Population.
    Inflamm Bowel Dis. 2024 Sep 3:izae188. doi: 10.1093.
    PubMed         Abstract available
    
    
11. MAHADEVAN U, Long M
    Low Placental Transfer Rates of Risankizumab Among Pregnant Women With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Aug 31:izae182. doi: 10.1093.
    PubMed        
    
    
12. WANG S, Xu Y, Wang L, Lin J, et al
    TolDC Restores the Balance of Th17/Treg via Aryl Hydrocarbon Receptor to Attenuate Colitis.
    Inflamm Bowel Dis. 2024;30:1546-1555.
    PubMed         Abstract available
    
    
13. GONZALEZ CG, Stevens TW, Verstockt B, Gonzalez DJ, et al
    Crohn's Patient Serum Proteomics Reveals Response Signature for Infliximab but not Vedolizumab.
    Inflamm Bowel Dis. 2024;30:1536-1545.
    PubMed         Abstract available
    
    
14. HE JZ, Hirschtritt ME, Wei J, Ramalingam ND, et al
    Psychiatric Diagnoses, Medication, and Service Use Among Patients Who Receive Emergency Care for Inflammatory Bowel Diseases.
    Inflamm Bowel Dis. 2024;30:1619-1622.
    PubMed        
    
    

    
    J Crohns Colitis

15. MOUTSOGLOU D, Syal A, Lopez S, Nelson EC, et al
    Novel Microbial Engraftment Trajectories following Microbiota Transplantation Therapy in Ulcerative Colitis.
    J Crohns Colitis. 2024 Sep 6:jjae142. doi: 10.1093.
    PubMed         Abstract available
    
    
16. PINTO S, Sajbenova D, Beninca E, Nooij S, et al
    Dynamics of Gut Microbiota after Fecal Microbiota Transplantation in Ulcerative Colitis: Success Linked to Control of Prevotellaceae.
    J Crohns Colitis. 2024 Sep 3:jjae137. doi: 10.1093.
    PubMed         Abstract available
    
    
17. VERSTOCKT B
    VIBRATO's Symphony: Orchestrating Biomarker Harmony for Ritlecitinib in UC Therapy.
    J Crohns Colitis. 2024;18:1359-1360.
    PubMed        
    
    
18. YOUSSEF M, Hossein-Javaheri N, Hoxha T, Mallouk C, et al
    Work Productivity Impairment in Persons with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.
    J Crohns Colitis. 2024;18:1486-1504.
    PubMed         Abstract available
    
    

    
    Lancet Gastroenterol Hepatol

19. KEDIA S, Ahuja V
    Infliximab rescue therapy in acute severe ulcerative colitis: more does not equal better.
    Lancet Gastroenterol Hepatol. 2024 Sep 2:S2468-1253(24)00229.
    PubMed        
    
    
20. CHOY MC, Li Wai Suen CFD, Con D, Boyd K, et al
    Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial.
    Lancet Gastroenterol Hepatol. 2024 Sep 2:S2468-1253(24)00200.
    PubMed         Abstract available
    
    

    
    Minerva Gastroenterol (Torino)

21. XIE F, Zhang Y, Wang T
    Effects of mesalazine suppository combined with Kangfuxin solution retention enema on inflammatory markers and adverse reactions in patients with active ulcerative colitis.
    Minerva Gastroenterol (Torino). 2024 Sep 5. doi: 10.23736/S2724-5985.24.03720.
    PubMed        
    
    

    
    PLoS One

22. LI J, Zhang C, Xu Y, Yang L, et al
    Efficacy and safety of berberine plus 5-ASA for ulcerative colitis: A systematic review and meta-analysis.
    PLoS One. 2024;19:e0309144.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

23. HUANG B, Yin T, Fu S, Liu L, et al
    Inflammation-oriented montmorillonite adjuvant enhanced oral delivery of anti-TNF-alpha nanobody against inflammatory bowel disease.
    Proc Natl Acad Sci U S A. 2024;121:e2320482121.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.